{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Three recent studies have explored the potential of long non‐coding RNAs (lncRNAs) as prognostic biomarkers across several cancer types. In the context of lung cancers, one study established a five‐lncRNA signature that robustly predicted overall survival in lung adenocarcinoma (LUAD)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Another study, focusing on lung squamous cell carcinoma (LUSC), identified a nine‐RNA molecular signature to predict recurrence after surgical resection in stage I–IIIA patients. Within this signature, LINC01322 was included as one of the contributing RNAs, suggesting that its aberrant expression is associated with the risk of cancer recurrence and may serve as a candidate marker for targeted treatment strategies in LUSC."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Although LINC01322 was not directly evaluated in the bladder cancer study—which developed a six‐lncRNA prognostic signature related to extracellular matrix signaling and immune cell infiltration"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": "—its inclusion in the LUSC signature underscores the broader potential of lncRNAs to impact tumorigenesis and clinical outcomes in lung cancer. Overall, the findings imply that dysregulation of LINC01322, along with other lncRNAs, may reflect underlying cancer-associated biological processes and hold prognostic significance, particularly in predicting tumor recurrence in LUSC.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Lizhong Zeng, Wei Wang, Yang Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A five-long non-coding RNA signature with the ability to predict overall survival of patients with lung adenocarcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Exp Ther Med (2019)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3892/etm.2019.8138"}], "href": "https://doi.org/10.3892/etm.2019.8138"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "31777562"}], "href": "https://pubmed.ncbi.nlm.nih.gov/31777562"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Li Sun, Juan Li, Xiaomeng Li, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A Combined RNA Signature Predicts Recurrence Risk of Stage I-IIIA Lung Squamous Cell Carcinoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Front Genet (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3389/fgene.2021.676464"}], "href": "https://doi.org/10.3389/fgene.2021.676464"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "34194476"}], "href": "https://pubmed.ncbi.nlm.nih.gov/34194476"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Liangliang Qing, Peng Gu, Mingsheng Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Extracellular Matrix-Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S284167"}], "href": "https://doi.org/10.2147/OTT.S284167"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33324071"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33324071"}]}]}]}